Open AccessAntithrombin-III for New Coronavirus Infection (COVID-19) Under Conditions of Extracorporeal Membrane Oxygenation (Clinical Observation)
Author(s) -
S. V. Zhuravel,
В. В. Владимиров,
Pavel Gavrilov,
Igor Ivanov,
С. С. Петриков,
K. A. Popugaev,
А. М. Талызин
Publication year - 2022
Publication title -
neotložnaâ medicinskaâ pomoŝʹ
Language(s) - English
Resource type - Journals
eISSN - 2541-8017
pISSN - 2223-9022
DOI - 10.23934/2223-9022-2021-10-4-642-648
Subject(s) - extracorporeal membrane oxygenation , medicine , covid-19 , thrombosis , coagulation , antithrombin , coronavirus , respiratory failure , extracorporeal , anesthesia , intensive care medicine , cardiology , disease , heparin , virology , infectious disease (medical specialty) , outbreak
COVID-19 is a disease that, in addition to respiratory failure, leads to thrombosis and bleeding due to coagulation disorders. Extracorporeal membrane oxygenation (ECMO), required in cases of a deterioration of gas exchange function of the lungs, contributes to changes in blood coagulation indicators, which leads to an increased risk of hemorrhagic complications and thrombosis. In the article, a clinical case of a severe course of COVID-19 is reported, which required ECMO. During the treatment, antithrombin-III was used, which allowed avoiding life-threatening complications and successfully completing the procedure.